NICE pricing reform 'not radical enough' says UK drug industry group
This article was originally published in SRA
NICE in the UK needs a "more radical" reform of its methods and processes than is currently being proposed in its consultation on value-based assessment (VBA), says the Association of the British Pharmaceutical Industry1-3.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.